Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Market-Moving News for April 28th

Author: Benzinga Newsdesk | April 28, 2025 06:28am

PRTG: 81% | Portage Biotech Reports Confirmatory Preclinical Efficacy Data For PORT-7 (TT-4). The New Data In A Murine Mesothelioma Model Demonstrated Single-Agent Activity For PORT-7 That Was Superior To Treatment With Single-Agent Anti-PD1 Antibody

 

AMPY: 34% | Amplify Energy shares are trading higher after the company announced its termination of the previously announced merger agreement with Juniper Capital

 

RVMD: 7% | Revolution Medicines shares are trading higher after the company announced new clinical data for zoldonrasib as monotherapy in patients with KRAS G12D mutant non-small cell lung cancer.

Posted In: AMPY PRTG RVMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist